MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
Architects: Cancer & Oncology Companies _Pharmaceuticals, Biotechnology & Technology _ Liver
Omega Therapeutics, Inc., (NASDAQ:OMGA)*
Organization & Developments: Omega Therapeutics
Parents
Omega Therapeutics, Inc., (NASDAQ:OMGA)*
Children
*Aims to treat inflammatory and immunological disorders, metabolic conditions, and rare diseases where a targeted approach to modulating the epigenome enables the company to hit disease targets previously considered “undruggable.”
*Omega’s drugs are fusion proteins made up of a delivery system that takes the therapy to specific cell types
*The company is working on a new class of treatments called “epigenomic controllers,” which are designed to adjust the expression of target genes.
2022: Omega Therapeutics Receives Orphan Drug Designation for OTX-2002 for the Treatment of Hepatocellular Carcinoma
2023: Omega Therapeutics: 2023 Could Well Be A Turning Point_ seekingalpha.com
2024: Omega Therapeutics And Novo Nordisk Collaboration: A Cautious 'Buy'_seekingalpha.com
2024: Omega Therapeutics: Starting 2024 With A Bang_ seekingalpha.com
2024: Omega Therapeutics: The Next Weight Loss Drug Runner_ seekingalpha.com
2025: Flagship spinout Omega is days away from bankruptcy, filing shows
Jumps
Finance & Acquisitions: Omega Therapeutics
Key People: Omega Therapeutics